ZyCal Bioceuticals Healthcare Company, Inc.
The FTC filed a federal complaint against ZyCal Bioceuticals Healthcare Company, Inc. and related party Excellent Marketing Results, Inc. (EMR) for making unsubstantiated health claims about Cyplexinol-based products marketed for joint pain, arthritis, bone tissue, and cartilage growth. EMR claimed its StimTein product was 'clinically proven' to stimulate bone and cartilage cell growth without adequate scientific support. EMR and its president settled, were barred from making unsupported health claims, and over $110,000 was returned to consumers; in February 2023, a proposed order was announced barring ZyCal defendants from the deceptive conduct alleged in the complaint.
Flagged claims (1)
clinically proven to stimulate cells to grow bone tissue and cartilage
Required actions (3)
prohibits them from making such health-related product claims unless they are supported by competent and reliable scientific evidence
the FTC announced it was returning more than $110,000 to consumers who bought EMR's StimTein
the FTC announced a proposed order barring the ZyCal defendants from the deceptive conduct alleged in the complaint
Does your site contain similar claims?
The free site audit scans your site against every entry in this Atlas. Most nutrition / supplements sites match 3-6 patterns.
Run my free site audit